LipoScience

The company is developing a new class of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. LipoScience’s proprietary NMR LipoProfile® test, its first marketed product, measures the number of low density lipoprotein particles(LDL-P) in blood to personalize management of risk for heart disease. The company recently received FDA clearance for Vantera®, an automated clinical analyzer that simplifies and automates. The company’s automated clinical analyzer, Vantera®, was cleared by the FDA in 2012.

LipoScience raised $45 million in its initial public offering in January 2013.

LipoScience

Raleigh, NC

09.25.2014
LabCorp Announces Agreement to Acquire LipoScience

Read More

01.22.2014
LipoScience Announces Appointment of Howard Doran as President an…

Read More